Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- De-escalation in breast cancer surgery.NPJ Breast Cancer. 2022; 8: 25
- De-escalating breast cancer surgery-where is the tipping point?.JAMA Oncol. 2020; 6: 183-184
- Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.JAMA. 2011; 305: 569-575
- Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.N Engl J Med. 2018; 379: 111-121
- 21-gene assay to inform chemotherapy benefit in node-positive breast cancer.N Engl J Med. 2021; 385: 2336-2347
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.Lancet Oncol. 2015; 16: 266-273
- Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review.JAMA Surg. 2020; 155: 759-770
- Conservation approaches for the management of stage I/II carcinoma of the breast: milan cancer institute trials.World J Surg. 1994; 18: 70-75
- Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials.N Engl J Med. 1995; 333: 1444-1455
- Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med. 2002; 347: 1233-1241
- Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.N Engl J Med. 2002; 347: 1227-1232
- Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.J Natl Cancer Inst. 2011; 103: 478-488
- Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.J Clin Oncol. 2013; 31: 4054-4059
- Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr. 2001; : 96-102
- Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.J Clin Oncol. 2001; 19: 4224-4237
- Neoadjuvant chemotherapy for operable breast cancer.Br J Surg. 2007; 94: 1189-1200
- Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.Ann Surg Oncol. 2014; 21: 704-716
- Variations in persistent use of low-value breast cancer surgery.JAMA Surg. 2021; 156: 353-362
- Trends in reoperation after initial lumpectomy for breast cancer: addressing overtreatment in surgical management.JAMA Oncol. 2017; 3: 1352-1357
- Evaluating the effect of margin consensus guideline publication on operative patterns and financial impact of breast cancer operation.J Am Coll Surg. 2018; 227: 6-11
- Changes in reoperation after publication of consensus guidelines on margins for breast-conserving surgery: a systematic review and meta-analysis.JAMA Surg. 2020; 155: e203025
- Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.J Clin Oncol. 2013; 31: 2382-2387
- Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.Cancer. 2006; 106: 4-16
- Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.Ann Surg. 2010; 251: 595-600
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.Lancet Oncol. 2010; 11: 927-933
- Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.JAMA. 2013; 310: 1455-1461
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.Lancet Oncol. 2013; 14: 609-618
- The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis.J Surg Oncol. 2011; 104: 97-103
- Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer.Br J Surg. 2018; 105: 1541-1552
- Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.Ann Surg Oncol. 2014; 21: 3231-3239
- Frequency of contralateral prophylactic mastectomy in breast cancer patients with a negative BRCA1 and BRCA2 rapid genetic test result.Ann Surg Oncol. 2021; 28: 4967-4973
- The LORIS trial: addressing overtreatment of ductal carcinoma in situ.Clin Oncol (R Coll Radiol). 2015; 27: 6-8
- The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA).J Clin Oncol. 2019; 37: TPS603
- The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).BMJ Open. 2019; 9: e026797
Francis A., Bartlett J., Billingham L., et al., Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. San Antonio Breast Symposium, San Antonio, TX. 2013.
- Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy.Ann Surg Oncol. 2019; 26: 3071-3079
- De-escalation towards omission is the tipping point of individualizing breast cancer surgery.Eur J Surg Oncol. 2020; 46: 1543-1545
- Prospective validation of a 21-gene expression assay in breast cancer.N Engl J Med. 2015; 373: 2005-2014
- Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx.J Clin Oncol. 2019; 37: 1956-1964
Kalinsky K, B.W., Meric-Bernstam F et al., SWOG S1007: Adjuvant trial randomized ER+ patients who had a recurrence score <25 and 1–3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy. Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS): San Antonio, TX, December 8–11, 2020. Abstract GS3-01.
- Postmenopausal Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy.Oncologist. 2021; 26: S11-S12
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy. 2022.
- Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.Lancet Oncol. 2019; 20: 352-360
- Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review.Radiat Oncol. 2020; 15: 17
- Survival of women with inflammatory breast cancer: a large population-based study.Ann Oncol. 2014; 25: 1143-1151
- Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.Ann Surg Oncol. 2002; 9: 235-242
- Pregnancy associated breast cancer.Breast J. 2020; 26: 81-85
- Pregnancy-associated breast cancer.Clin Obstet Gynecol. 2016; 59: 779-788
- Reducing overtreatment of cancer with precision medicine: just what the doctor ordered.JAMA. 2018; 319: 1091-1092
- Conceptualizing de-implementation in cancer care delivery.J Clin Oncol. 2019; 37: 93-96
- Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007.Ann Surg Oncol. 2007; 14: 2425-2427
- Barriers and Facilitators to De-Implementation of the Choosing Wisely(®) Guidelines for Low-Value Breast Cancer Surgery.Ann Surg Oncol. 2020; 27: 2653-2663
- Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.BMC Cancer. 2022; 22: 141
- Financial costs and burden related to decisions for breast cancer surgery.J Oncol Pract. 2019; 15: e666-e676
- Too much surgery: overcoming barriers to deimplementation of low-value surgery.Ann Surg. 2020; 271: 1020-1022
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
